Composes aminomethyls cycliques substitues et medicaments contenant lesdits composes

Cyclical substituted aminomethyl compounds and medicaments containing these compounds

The invention relates to cyclic substituted aminomethyl compounds of general formula IA and IB, methods for production thereof, intermediates in said production methods, a medicament containing at least one of said cyclic substituted aminomethyl compounds, the use of said cyclic substituted aminomethyl compounds for the production of a medicament for the treatment of pain, incontinence, pruritus, tinnitus aurium and/or diarrhoea and pharmaceutical compositions containing said compounds.
Abstract

The invention relates to cyclic substituted aminomethyl compounds of general formula IA and IB, methods for production thereof, intermediates in said production methods, a medicament containing at least one of said cyclic substituted aminomethyl compounds, the use of said cyclic substituted aminomethyl compounds for the production of a medicament for the treatment of pain, incontinence, pruritis, tinnitus aurium and/or diarrhoea and pharmaceutical compositions containing said compounds.
Cyclic substituted aminomethyl compounds and medicaments comprising these compounds

The present Application relates to cyclic substituted aminomethyl compounds, processes for their preparation, intermediate compounds of these processes, medicaments comprising at least one of the cyclic substituted aminomethyl compounds, the use of the cyclic substituted aminomethyl compounds for the preparation of a medicament for treatment of pain, urinary incontinence, itching, tinnitus aurium and/or diarrhoea and pharmaceutical compositions comprising these compounds.

Treatment of chronic and non-chronic states of pain is of great importance in medicine. There is a world-wide need for therapies which have a good action for target-orientated treatment of chronic and non-chronic states of pain appropriate for the patient, by which is to be understood successful and satisfactory pain treatment for the patient.

Conventional opioids, such as morphine, have a good action in the treatment of severe to very severe pain. However, their use is limited by the known side effects, such as e.g. respiratory depression, vomiting, sedation, constipation and development of tolerance. Furthermore, they are less active on neuropathic or incidental pain, from which tumour patients in particular suffer.

Opioids display their analgesic action by binding to receptors on the membrane which belong to the family of so-called G protein-coupled receptors. Biochemical and pharmacological characterization of, for example, μ-, κ- and δ-subtypes of these receptors has aroused the hope that
subtype-specific opioids have a different action/side
effects profile to the conventional opioids, such as e.g.
morphine. Morphine binds selectively to so-called μ-
receptors. On the other hand, compounds with an
antinociceptive potential which do not bind or scarcely
bind to μ-receptors and the analgesic action of which is
mediated exclusively or predominantly via δ-receptors are
known.

DE 197 55 480 A1 thus discloses substituted heterocyclic
benzocycloalkenes, the analgesic activity of which is
mediated largely or exclusively via δ-receptors.
Substituted amino compounds with a corresponding biological
activity are known from DE 198 05 370 A1.

The present invention is based on the object of providing
compounds which have an analgesic action and are suitable
for pain treatment - in particular also for treatment for
chronic and neuropathic pain. These substances moreover
should as far as possible cause none of the side effects
which usually occur when opioids with μ-receptor affinity
are used, such as e.g. nausea, vomiting, dependency,
respiratory depression or constipation.

This object is achieved by cyclic substituted aminomethyl
compounds of the general formula IA and/or IB which, in
accordance with the object, show no or only a low affinity
for μ-receptors and moreover surprisingly have an analgesic
action in vivo, although in vitro they also show no
specific activity on opiate δ-receptors.
The compounds according to the invention are cyclic substituted aminomethyl compounds of the general formula IA and/or IB.

wherein

- $R^1$ denotes H, F, Cl, OH, O-CH$_3$, O-(C$_2$-6-alkyl), O-(C$_3$-7-cycloalkyl), CH$_3$, C$_2$-6-alkyl, CH$_2$F, CHF$_2$ or CF$_3$, in each case in the 2-, 3-, 4-, 5- or 6-position of the phenyl ring,

- $R^2$ denotes H, F, Cl, CH$_3$, C$_2$-6-alkyl, CH$_2$F, CHF$_2$ or CF$_3$, in each case in the 2-, 3-, 4-, 5- or 6-position of the phenyl ring,

- $R^3$ and $R^4$ independently of one another denote H, F, Cl, OH, O-CH$_3$, O-(C$_2$-6-alkyl), O-(C$_3$-7-cycloalkyl), CH$_3$, C$_2$-6-alkyl, CH$_2$F, CHF$_2$, CF$_3$, O-aryl, aryl or heterocyclyl, in each case in the $\alpha$-, $\beta$-, $\gamma$- and/or $\delta$-position of the aromatic ring,
R⁵ and R⁶ independently of one another denote CH₃, C₂-₆-alkyl, C₃-₇-cycloalkyl, CH₂-(C₃-₇-cycloalkyl), aryl, (C₁₋₆-alkyl)-aryl, heterocyclyl or (C₁₋₆-alkyl)-heterocyclyl,

X denotes CH₂, O, S, SO or SO₂,

n is 0, 1, 2 or 3 if X denotes CH₂ and is 1, 2 or 3 if X denotes O, S, SO or SO₂,

and the configuration of the exocyclic double bond in compounds of the general formula IB is E or Z,

and their pharmaceutically acceptable salts.

The compounds according to the invention show, without affinity for µ-receptors, a significant analgesic action without at the same time having a specific activity on δ-receptors. The manner in which the compounds according to the invention mediate their analgesic action and via which opiate receptor subtypes may do so has not yet been clarified.

The term "C₂₋₆-alkyl" in the context of this invention includes acyclic saturated or unsaturated hydrocarbon radicals, which can be branched- or straight-chain and unsubstituted or mono- or polysubstituted, having 2, 3, 4, 5 or 6 carbon atoms, i.e. C₂₋₆-alkyls, C₂₋₆-alkenyls and C₂₋₆-alkinyls. C₂₋₆-Alkyl is advantageously chosen from the group which comprises ethyl, n-propyl, 2-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl, n-hexyl, 2-hexyl; ethylenyl (vinyl), ethinyl, propenyl (-CH₂CH=CH₂, -CH=CH-CH₃, -C(=CH₂)-CH₃), propinyl
(-CH-C≡CH), butenyl, butinyl, pentenyl, pentinyl, hexenyl and hexinyl.

The term "C₃₋₇-cycloalkyl" for the purpose of this invention denotes cyclic hydrocarbons having 3, 4, 5, 6 or 7 carbon atoms, which can be saturated or unsaturated, unsubstituted or mono- or polysubstituted. C₃₋₇-Cycloalkyl is advantageously chosen from the group which comprises cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl and cycloheptenyl.

The term "aryl" in the context of this invention denotes, inter alia, phenyls, naphthyls or anthracenyls. The aryl radicals can also be fused with further saturated, (partly) unsaturated or aromatic ring systems. Each aryl radical can be present in unsubstituted or mono- or polysubstituted form, it being possible for the substituents on the aryl to be in any desired position of the aryl. Aryl is advantageously chosen from the group which comprises, phenyl, p-toluyl, p-methoxyphenyl, xylyl, 1-naphthyl, 2-naphthyl and 4-biphenyl. Preferred substituents are OH, F, Cl, Br, C₁₋₆-alkyl, C₃₋₇-cycloalkyl, CH₂F, CHF₂, CF₃, O-C₁₋₆-alkyl, O-C₃₋₇-cycloalkyl, O-CH₂-C₃₋₇-cycloalkyl, heterocyclyl, phenyl and naphthyl.

The term "heterocyclyl" represents a 5-, 6- or 7-membered cyclic organic radical which contains at least 1, optionally also 2, 3, 4 or 5 heteroatoms, it being possible for the heteroatoms to be identical or different and for the cyclic radical to be saturated, unsaturated or aromatic, unsubstituted or mono- or polysubstituted. The heterocyclic radical can also be part of a bi- or polycyclic system. Preferred heteroatoms are nitrogen,
oxygen and sulfur. It is preferable for the heterocyclyl radical to be chosen from the group which comprises
pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyranyl, indolyl,
indazolyl, purinyl, pyrimidinyl, indolizinyl, quinolinyl, isoquinolinyl, quinazolinyi, carbazolyl, phenazinyl,
phenothiazinyl, pyrroldinyl, piperidinyl, piperazinyl and morpholinyl, it being possible for bonding to the nitrogen
atom, the aryl ring(s) the phenyl ring or the aromatic ring
of the compounds of the general formulae IA and IB
according to the invention to be via any desired ring
member of the heterocyclyl radical.

The terms "C_{1-6}-alkyl-aryl" and "C_{1-6}-alkyl-heterocyclyl" for
the purpose of the present invention mean that C_{1-6}-alkyl,
aryl and heterocyclyl have the meanings defined above and
are bonded to the aromatic ring or the nitrogen atom of the
aminomethyl radical of the compounds of the formula IA
and/or IB via a C_{1-6}-alkyl group.

In connection with "alkyl", "alkoxy", "alkenyl" and
"alkynyl", the term "substituted" is understood in the
context of this invention as meaning the replacement of a
hydrogen radical by F, Cl, Br, I, NH_{2}, SH or OH,
polysubstituted radicals being understood as meaning those
radicals which are substituted several times, e.g. twice or
three times, both on different and on the same atoms, for
example three times on the same C atom, as in the case of
CF_{3} or -CH_{2}CF_{3}, or at different places, as in the case of
-CH(\text{OH})-CH=CH-\text{CHCl}_{2}. Polysubstitution can be with identical
or with different substituents.
In respect of "aryl", "alkyl-aryl", "heterocyclyl", "alkyl-heterocyclyl" and "cycloalkyl" or "CH\textsubscript{2}-(C\textsubscript{3}-\textsubscript{7}-cycloalkyl)", in the context of this invention "mono- or polysubstituted" is understood as meaning one or more, e.g. two, three or four, replacements of one or more hydrogen atoms of the ring system by F, Cl, Br, I, NH\textsubscript{2}, SH, OH, CF\textsubscript{3}, NO\textsubscript{2}, SO\textsubscript{2}H, C(O)OH; =O or =S; mono- or polysubstituted or unsubstituted C\textsubscript{1-6}-alkanyl, C\textsubscript{2-6}-alkenyl, C\textsubscript{2-6}-alkynyl, O-C\textsubscript{1-6}-alkyl, -C(O)O-C\textsubscript{1-6}-alkyl, -C\textsubscript{1-6}-alkyl-C(O)O-C\textsubscript{1-6}-alkyl; mono- or polysubstituted or unsubstituted phenyl, benzyl, napthyl or heterocyclyl; on one or optionally different atoms. The polysubstitution here is with identical or with different substituents.

The radicals R\textsuperscript{1} and R\textsuperscript{2} can in each case be provided in the 2-, 3-, 4-, 5- or 6-position of the phenyl ring, i.e. in the ortho-, meta- or para-position.

The radicals R\textsuperscript{3} and R\textsuperscript{4} can in each case be provided in the α-, β-, γ- or δ-position of the aromatic ring.

X in the compounds of the formulae IA and IB according to the invention denotes CH\textsubscript{2} (methylene), O (oxygen), S (sulfur), SO (sulfoxide) or SO\textsubscript{2} (sulfone), while n is 0, 1, 2 or 3 in the case where X denotes CH\textsubscript{2} or is 1, 2 or 3 in the case where X denotes O, S, SO or SO\textsubscript{2}. If X = CH\textsubscript{2}, the compounds of the general formulae IA and IB are e.g. indane or indene derivatives (n = 0), dihydro- or tetrahydronaphthalene derivatives (n = 1), benzocycloheptyl derivatives (n = 2) or benzocyclooctyl derivatives (n = 3).

If X represents oxygen or sulfur, the compounds according to the invention are e.g. for n = 2 oxepine or thiepine
derivatives respectively. If \( X = \text{SO} \), cyclic sulfoxides are present, and if \( X = \text{SO}_2 \), cyclic sulfones are present.

The cyclic substituted aminomethyl compounds of the general formula IB according to the invention can be either in the \( E \) or in the \( Z \) configuration or as a mixture of the two configurations. For the purpose of this invention, \( E \) configuration is understood as meaning that stereochemical arrangement in which the phenyl ring substituted by \( R^1 \) and \( R^2 \) and the aromatic ring substituted by \( R^3 \) and \( R^4 \) are trans with respect to one another, while in the \( Z \) configuration the two rings are arranged cis with respect to one another:

![Chemical Structure](image)

15 Pharmaceutically acceptable salts in the context of this invention are those salts of the compounds according to the general formulae IA and/or IB according to the invention which are physiologically tolerated during pharmaceutical use - in particular during use on mammals and/or humans.  

Such pharmaceutically acceptable salts can be formed, for example, with inorganic or organic acids, preferably with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, p-toluenesulfonic acid, carbonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid or aspartic acid.
The salts formed are, inter alia, hydrochlorides, hydrobromides, phosphates, carbonates, bicarbonates, formates, acetates, oxalates, succinates, tartrates, fumarates, citrates and glutamates. The hydrates of the compounds according to the invention, which can be obtained e.g. by crystallization from aqueous solution, are also preferred.

A group of preferred compounds of the present invention is formed by those cyclic substituted aminomethyl compounds of the general formula IA in which, independently of one another, $R^1$ denotes OH, O-CH$_3$ or Cl, $R^2$ denotes H or Cl, $R^3$ denotes H or OH, $R^4$ denotes H, $R^5$ and $R^6$ denote CH$_3$ and X denotes CH$_2$, O, S or SO and n is 1 or 2, and their pharmaceutically acceptable salts. Particularly preferred compounds of the general formula IA here are those in which, independently of one another, $R^1$ denotes 3-OH, 2-O-CH$_3$, 3-O-CH$_3$ or 4-Cl, $R^2$ denotes H, 2-Cl or 4-Cl, $R^3$ denotes H, $\alpha$-OH or $\beta$-OH, $R^4$ denotes H, $R^5$ and $R^6$ denote CH$_3$ and X denotes CH$_2$, O, S or SO and n is 1 or 2, and pharmaceutically acceptable salts thereof.

Another group of preferred compounds of the present invention is formed by those cyclic substituted aminomethyl compounds of the general formula IB in which $R^1$ denotes OH, O-CH$_3$ or Cl, $R^2$, $R^3$ and $R^4$ denote H, $R^5$ and $R^6$ denote CH$_3$ and X denotes CH$_2$, O or S, n is 1 or 2 and the configuration of the exocyclic double bond is E or Z, and their pharmaceutically acceptable salts. Particularly preferred cyclic substituted aminomethyl compounds of the formula IB here are those in which $R^1$ is 3-OH, 2-O-CH$_3$, 3-O-CH$_3$ or 4-Cl, $R^2$, $R^3$ and $R^4$ are H, $R^5$ and $R^6$ are CH$_3$ and X is CH$_2$, O or
S, n is 1 or 2 and the configuration of the exocyclic double bond is E or Z, and their pharmaceutically acceptable salts.

5 It is moreover preferable that the compounds of the general formulae IA and/or IB according to the invention are in the form of a mixture of the isomers with an endocyclic and exocyclic double bond, i.e. as a mixture of compounds which differ only in the position of the aliphatic double bond in the ring containing the group X or outside the ring containing the group X, but in which the definition of R^1 or R^6, X and n coincides. The ratio of isomers in this mixture can vary. The ratio of the endo and exo compounds of the formulae IA and IB e.g. can be in a range from 100:1 to 1:100. The ratio is preferably 1:1, 1:2, 2:1, 1:10, 10:1, 1:100 or 100:1.

The compounds of the general formulae IA and/or IB according to the invention can be – where they are optically active substances – in the form of their racemates, in the form of the pure enantiomers and/or diastereomers or in the form of mixtures of these enantiomers or diastereomers, and in particular both in substance and as pharmaceutically acceptable salts of these compounds. This applies in particular to compounds of the general formula IB which always have an asymmetric centre in the allylic position, marked with an asterisk *, to the exocyclic double bond:
The mixtures can be in any desired mixing ratio of the enantiomers or diastereomers contained in them. The compounds according to the invention or their pharmaceutically acceptable salts are preferably in the enantiomerically pure form.

The following compounds according to the invention are particularly preferred:

\[ 1-(4\text{-chlorobenzyl})-3,4\text{-dihydro-naphth}-2\text{-ylmethyl}]\text{-dimethylamine,} \]
\[ 3-(2\text{-dimethylaminomethyl}-3,4\text{-dihydro-naphth}-1\text{-yl-methyl})\text{-phenol,} \]
\[ 5-(4\text{-chlorobenzyl})-6\text{-dimethylaminomethyl}-7,8\text{-dihydro-naphth}-1\text{-ol,} \]
\[ E-(5RS)-5-(4\text{-chlorobenzylidene})-6,7,8,9\text{-tetrahydro-5H-benzocyclohepten}-6\text{-ylmethyl}]\text{-dimethylamine,} \]
\[ Z-(4RS)-5-(4\text{-chlorobenzylidene})-2,3,4,5\text{-tetrahydrobenzo}[b]\text{oxepin}-4\text{-ylmethyl}]\text{dimethylamine,} \]
\[ E-(4RS)-3-(4\text{-dimethylaminomethyl}-3,4\text{-dihydro-2H-benzo}[b]\text{oxepin}-5\text{-ylidenemethyl})\text{-phenol or} \]
\[ Z-(4RS)-3-(4\text{-dimethylaminomethyl}-3,4\text{-dihydro-2H-benzo}[b]\text{oxepin}-5\text{-ylidenemethyl})\text{-phenol,} \]
and their pharmaceutically acceptable salts, in particular their hydrochlorides, and in particular both in racemic and in non-racemic and in enantiomerically pure form. E-(4RS)-3-(4-Dimethylaminomethyl-3,4-dihydro-2H-benzo[b]oxepin-5-ylidenemethyl)-phenol in the form of its hydrochloride is particularly preferred.

The invention also provides a process for the preparation of the compounds of the general formulae IA and/or IB according to the invention.

\[
\begin{align*}
\text{wherein} & \\
R^1 & \text{denotes H, F, Cl, OH, O-CH}_3, \text{O-}(C_{2-6}-\text{alkyl}), \text{O-}(C_{3-7}-\text{cycloalkyl}), \text{CH}_3, \text{C}_{2-6}-\text{alkyl, CH}_2F, \text{CHF}_2 \text{ or CF}_3, \text{in each case in the 2-, 3-, 4-, 5- or 6-} \\
\text{position of the phenyl ring,} & \\
R^2 & \text{denotes H, F, Cl, CH}_3, \text{C}_{2-6}-\text{alkyl, CH}_2F, \text{CHF}_2 \text{ or CF}_3, \text{in each case in the 2-, 3-, 4-, 5- or 6-} \\
\text{position of the phenyl ring,} & \\
R^3 \text{ and } R^4 & \text{independently of one another denote H, F, Cl, OH,} \\
\text{O-CH}_3, \text{O-}(C_{2-6}-\text{alkyl}), \text{O-}(C_{3-7}-\text{cycloalkyl}), \text{CH}_3, & \\
\text{C}_{2-6}-\text{alkyl, CH}_2F, \text{CHF}_2, \text{CF}_3, \text{O-aryl, aryl or} & \\
\text{heterocyclyl, in each case in the } \alpha-, \beta-, \gamma- & \\
\text{and/or } \delta-\text{position of the aromatic ring,} & 
\end{align*}
\]
R⁵ and R⁶ independently of one another denote CH₃, C₂-₆-alkyl, C₃-₇-cycloalkyl, CH₂-(C₃-₇-cycloalkyl), aryl, (C₁-₆-alkyl)-aryl, heterocyclyl or (C₁-₆-alkyl)-heterocyclyl,

5 X denotes CH₂, O, S, SO or SO₂,

n is 0, 1, 2 or 3 if X denotes CH₂ and is 1, 2 or 3 if X denotes O, S, SO or SO₂,

and the configuration of the exocyclic double bond in compounds of the general formula IB is E or Z,

10 wherein the process according to the invention is characterized by a process step (a) which comprises the reaction of a tertiary alcohol of the general formula II

![Chemical Structure](image)

wherein R¹ to R⁶, X and n are as defined above, with an acid.

The use of half-concentrated or concentrated organic or inorganic acids is preferred here, in particular hydrochloric acid (HCl), e.g. 6N hydrochloric acid,

20 optionally in an aqueous or an organic solvent, such as e.g. diethyl ether, concentrated hydrobromic acid (HBr), hydrogen bromide in glacial acetic acid (HBr/HOAc), e.g. a 33% hydrogen bromide solution in glacial acetic acid, methanesulfonic acid, methanesulfonic acid with methionine and formic acid.
Process step (a) is conventionally carried out at a temperature of about 0°C to about 120°C.

By choice of a suitable acid, the preferred formation either of the endo isomer of the formula IA or of the exo isomer(s) of the formula IB can also be achieved. The use of HBr in glacial acetic acid as the acid in process step (a) thus preferentially forms the endo compound IA, while, for example, the exo products IB are predominantly formed if 6N HCl is employed.

The compounds of the general formulae IA and IB formed by the process according to the invention and present in a mixture after carrying out process (a) can of course also be separated from one another by means of conventional separation methods, it also being possible to achieve separation of the particular exo-\(\text{E}\) isomer of the formula IB from the corresponding exo-\(\text{Z}\) isomer of the formula IB.

Suitable methods which may be mentioned by way of example are chromatographic separation processes, in particular liquid chromatography processes under normal pressure or increased pressure, preferably MPLC and HPLC processes, and crystallization processes. The enantiomers and/or diastereomers of the compounds IA and IB according to the invention formed can moreover also be separated from one another with the aid of these and further processes known in the prior art, e.g. HPLC on chiral phases or fractional crystallization of diastereomeric salts formed with optically acid acids, such as (+)-tartaric acid, (-)-tartaric acid or (+)-10-camphorsulfonic acid.
Determination and assignment of the stereochemistry of the products prepared according to the invention, i.e.
identification of the particular endo and exo double bond isomers and of the E and Z isomers, takes place with the
aid of methods known in the prior art, for example by means of nuclear magnetic resonance spectroscopy (NMR) processes
which are well-known in the prior art. Thus e.g. the exo
isomers of the formula IB are differentiated from the endo
isomers of the formula IA with the aid of the chemical
shift of the benzylic hydrogen atom(s) in the $^1$H-NMR
spectrum. On the other hand, assignment of E/Z isomerism
is possible via the different chemical shift of the phenyl
ring protons in the $^1$H-NMR spectrum due to anisotropy
effects.

A preferred embodiment of the process according to the
invention is characterized in that process step (a)
comprises conversion of a tertiary alcohol of the general
formula II in which at least one of the radicals $R^1$, $R^2$ and
$R^4$ denotes $O-CH_3$ into compounds of the general formulae IA
and/or IB in which the radicals $R^1$, $R^2$ and $R^4$ denote OH,
when the corresponding radicals $R^1$, $R^2$ and $R^4$ in the
tertiary alcohol of the general formula II denote $O-CH_3$,
with a reagent from the group which comprises hydrogen
bromide in glacial acetic acid, concentrated hydrobromic
acid and methanesulfonic acid/methionine. The process step
is preferably carried out at a temperature of between 0°C
and 120°C, in particular at a temperature of between 20°C
and 50°C.

Another preferred embodiment of the process according to
the invention is characterized in that, before process step
(a), a process step (b) is carried out, which comprises conversion of a tertiary alcohol of the general formula III

\[
\begin{array}{c}
\text{III} \\
\end{array}
\]

wherein

\[
\begin{align*}
R^2, R^3, R^6, X \text{ and } n & \text{ are as defined above,} \\
R^7 & \text{ denotes } H, F, Cl, O-CH_3, O-(C_2-6-alkyl), O-(C_3-7-cycloalkyl), O-CH_2-phenyl, O-SiR^{10}R^{11}R^{12}, \text{ wherein } R^{10}, R^{11} \text{ and } R^{12} \text{ independently of one another are } \\
& \text{CH}_3, C_2-6-alkyl \text{ or phenyl, CH}_3, C_2-6-alkyl, \text{CH}_2F, \text{CHF}_2 \text{ or CF}_3, \text{in each case in the 2-, 3-, 4-, 5- or } \\
& 6\text{-position of the phenyl ring,} \\
R^8 \text{ and } R^9 & \text{ independently of one another denote } H, F, Cl, O- \\
& \text{CH}_3, O-(C_2-6-alkyl), O-(C_3-7-cycloalkyl), O-CH_2-phenyl, O-SiR^{10}R^{11}R^{12}, \text{ wherein } R^{10}, R^{11} \text{ and } R^{12} \\
& \text{independently of one another are } \text{CH}_3, C_2-6-alkyl \text{ or phenyl, CH}_3, C_2-6-alkyl, \text{CH}_2F, \text{CHF}_2, \text{CF}_3, \text{O-aryl,} \\
& \text{aryl or heterocyclyl, in each case in the } \alpha-, \beta-, \\
& \gamma- \text{ and/or } \delta\text{-position of the aromatic ring,} \\
& \text{and at least one of the radicals } R^7, R^8 \text{ and } R^9 \\
& \text{is } O-\text{CH}_3, O-(C_2-6-alkyl), O-(C_3-7-cycloalkyl), O- \\
& \text{CH}_2-phenyl \text{ or } O-SiR^{10}R^{11}R^{12}, \quad \text{into a tertiary alcohol of the general formula II in which } \\
R^1, R^3 \text{ and } R^4 & \text{ is [sic] in each case OH, when the } \\
& \text{corresponding radical } R^7, R^8 \text{ or } R^9 \text{ in the formula III is } O- \\
& \text{CH}_3, O-(C_2-6-alkyl), O-(C_3-7-cycloalkyl), O-\text{CH}_2-phenyl \text{ or } O-
\end{align*}
\]
SiR^{10}R^{11}R^{12}. If at least one of the radicals R^7, R^8 and R^9 represents a silanyloxy group (= O-SiR^{10}R^{11}R^{12}), O-SiR^{10}R^{11}R^{12} preferably represents a trimethylsilyloxy, tert-butyldiphenylsilyloxy or tert-butyldimethylsilyloxy group.

5 If R^7, R^8 and/or R^9 represent a benzyloxy group (= O-CH_2-phenyl), process step (b) expediently comprises reductive debenzylation with catalytically activated hydrogen. Platinum or palladium, inter alia, can be used as the catalyst here, it being possible for the transition metal to be absorbed e.g. on a suitable support material, such as active charcoal. The reaction is preferably carried out in an organic solvent, e.g. acetic acid, methanol, ethanol, 2-propanol, 1-propanol, 1-butanol, 2-butanol or tert-butanol, under pressures of 1 bar (10^5 Pa) to 100 bar (10^7 Pa) and at temperatures of about 20°C to about 100°C. The tertiary alcohols of the general formula III are preferably employed here in the form of one of their salts.

20 On the other hand, if R^7, R^8 and/or R^9 represent a silanyloxy group, process step (b) is preferably carried out either by treatment of the tertiary alcohol III with a fluoride anion, in particular tetra-n-butylammonium fluoride, in an inert solvent, such as e.g. tetrahydrofuran (THF), 1,4-dioxane or diethyl ether, preferably at room temperature, or by the action of methanolic hydrochloric acid.

25 If R^7, R^8 and/or R^9 in the tertiary alcohol of the general formula III represent methoxy (O-CH_3), O-(C_2-6-alkyl) or O-(C_3-7-cycloalkyl), process step (b) can be carried out by reaction of the compound III with diisobutylaluminium hydride in an aromatic hydrocarbon, such as toluene,
preferably at a temperature of between about 60°C and 130°C.

The new tertiary alcohols of the general formulae II and III which can be used for preparation of the cyclic substituted aminomethyl compounds of the general formulae IA and IB according to the invention form part of the present invention and can be obtained as intermediate compounds in a further process step (c), which is explained below, and then either purified and isolated by known methods or converted directly into the compounds of the formulae IA and/or IB by carrying out process steps (a) or (a) and (b) described above.

The tertiary alcohols II and III are preferably obtained here via a process step (c) which comprises reaction of a ketone of the general formula IV

![Chemical structure](image)

wherein $R^5$, $R^6$, $R^8$ and $R^9$, $X$ and $n$ are as defined above, with an organometallic compound of the general formula V
wherein $R^2$ and $R'$ are as defined above and $Z$ denotes MgCl, MgBr, MgI or Li.

5

Process step (c) is suitably carried out in an ether solvent, preferably an aliphatic or cycloaliphatic ether, such as e.g. diethyl ether or THF, at a temperature of, in particular, between -70°C and +60°C.

10

The ketones of the general formula IV employed in process step (c) are obtainable as Mannich bases, for example by a general process which is known e.g. from DE 197 55 480 A1 and DE 198 05 370 A1 and described inter alia by P. Horstmann and B. Unterhalt, Arch. Pharm. Med. chem. 330, 362-364 (1997), from the corresponding ketone VI, formaldehyde and the amine VII (see equation 1):
In the compounds of the general formulae IV, VI and VII, \( R^5, R^6, R^8, R^9 \) X and \( n \) are as defined above. The compounds of the formula VI, where they are not commercially obtainable, are accessible, for example, from the corresponding carboxylic acids of the general formula VIII by intramolecular Friedel-Crafts acylation by means of a Lewis acid or a proton acid, such as e.g. polyphosphoric acid (see e.g. J. March: Advanced Organic Chemistry, 3rd ed., John Wiley & Sons, New York, Chichester, Brisbane, Toronto, Singapore (1985), pages 484 to 487):

![Chemical Structure](image)

The organometallic compounds of the general formula V where \( Z = \text{MgCl}, \text{MgBr}, \text{MgI} \) or Li, where they are not commercially obtainable, are accessible, for example, by generally known processes by reaction of the corresponding chlorides, bromides or iodides, i.e. compounds of the formula V where \( Z = \text{Cl}, \text{Br} \) or I, with magnesium in an inert solvent by the Grignard method or with an organolithium reagent, e.g. \( n \)-butyllithium in \( n \)-hexane. The corresponding chlorides, bromides and iodides of the general formula V where \( Z = \text{Cl}, \text{Br} \) and I are in their turn either commercially available or accessible e.g. by reaction of the corresponding benzyl alcohols of the formula V where \( Z = \text{OH} \) with suitable chlorinating, brominating or iodinating reagents (see, for example, J. March: Advanced Organic Chemistry, 3rd ed.,

Where \( R^7, R^8 \) and/or \( R^9 \) in the compounds of the general

5 formulae IV, V, VI and VIII denote \( O-\text{CH}_3, O-(\text{C}_2\text{-}_6\text{-alkyl}), O-(\text{C}_3\text{-}_7\text{-cycloalkyl}), O-\text{CH}_2\text{-phenyl} \) or \( O-\text{SiR}^{10}\text{R}^{11}\text{R}^{12} \), these alkoxy, benzyloxy and silanyloxy compounds can be obtained from the corresponding hydroxy compounds, i.e. those compounds of the general formulae IV, V, VI and VIII in which \( R^7, R^8 \)

10 and/or \( R^9 \) represent OH, by introduction of suitable protective groups by generally known processes, such as are described, for example, in T.W. Greene, P.G.M. Wuts: Protective Groups in Organic Synthesis, 1st ed., John Wiley & Sons, New York, Chichester, Brisbane, Toronto, Singapore (1991).

Another preferred embodiment of the process according to the invention comprises a process step (d) in which compounds of the general formulae IA and/or IB in which \( X \)

20 denotes \( S \) and \( R^2 \) to \( R^6 \) and \( n \) are as defined above are converted into the corresponding compounds IA and/or IB where \( X = \text{SO} \) and/or \( \text{SO}_2 \) using an oxidizing agent. The oxidation of the sulfide (\( X = S \)) of the general formula IA and/or IB to the corresponding sulfoxide (\( X = \text{SO} \)) can be carried out, inter alia, with one equivalent of hydrogen peroxide (30 wt.% solution in water) in a suitable solvent, e.g. acetic acid, at a temperature of between about 20\(^\circ\)C and 60\(^\circ\)C, and the oxidation to the sulfone (\( X = \text{SO}_2 \)) can be carried out with a further equivalent of hydrogen peroxide.

30 Further suitable oxidizing agents are, inter alia, sodium perborate, t-butyl hypochlorite, sodium periodate and potassium hydrogen persulfate (Oxone\textsuperscript{®}) (see also J. March:

5 It is furthermore preferable, for conversion of compounds of the general formulae IA and/or IB in which at least one of the radicals \( R^1 \), \( R^3 \) and \( R^4 \) denotes O-CH\(_3\) into compounds of the general formulae IA and/or IB in which the corresponding radical(s) \( R^1 \), \( R^3 \) and \( R^4 \) denote(s) OH, to carry out a process step (e) after process step (a) and optionally before or after process step (d). This process step (e) can be carried out e.g. using diisobutylaluminium hydride in an aromatic hydrocarbon, such as e.g. toluene or xylene, at a temperature of 60°C to 130°C. An alternative procedure for step (e) comprises reaction with methanesulfonic acid/methionine at a temperature of 20°C to 50°C.

It is moreover preferred to carry out, after process step (a) or (d) or (e), a process step (f) which comprises conversion of the compounds IA and/or IB according to the invention into their pharmaceutically acceptable salts. Process step (f) is preferably carried out here by reaction of the compounds IA and/or IB, in the liquid or solid phase, with inorganic or organic acids - which can optionally also be bonded to a solid phase - such as, preferably, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, carbonic acid, p-toluenesulfonic acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid or aspartic acid, which form physiologically tolerated and therefore pharmaceutically acceptable salts with the
compounds IA and/or IB according to the invention. The salts formed are, inter alia, hydrochlorides, hydrobromides, phosphates, carbonates, bicarbonates, formates, acetates, oxalates, succinates, tartrates, fumarates, citrates and glutamates. The salt formation is preferably carried out in an organic solvent, such as e.g. diethyl ether, diisopropyl ether, alkyl acetates, acetone or methyl ethyl ketone. The particularly preferred hydrochlorides of the compounds according to the invention are accessible, in particular, by carrying out process step (f) with trimethylchlorosilane in an aqueous organic solvent. The hydrates, such as e.g. mono-, sesqui-, di-, tri- and tetrahydrates, are furthermore preferred salts of the compounds according to the invention which can be obtained, for example by crystallization from aqueous solution.

In another preferred process step (g), which can be carried out after process step (a) or before or after process step (d) or before or after process step (e) or after process step (f), the compounds of the general formulae IA and IB or their pharmaceutically acceptable salts are separated from one another. The separation can be carried out by means of known separation processes, it also being possible to achieve separation of the particular exo-\(E\) isomer of the formula IB from the corresponding exo-\(Z\) isomer of the formula IB. Suitable methods are e.g. chromatographic separation processes, in particular liquid chromatography processes under normal or increased pressure, preferably MPLC and HPLC processes, and processes of fractional crystallization. The enantiomers and/or diastereomers of the compounds IA and IB according to the invention formed can moreover also be separated from one another with the
aid of these and further processes known in the prior art, e.g. HPLC on chiral phases or fractional crystallization of diastereomeric salts formed with chiral acids, such as (+)-tartaric acid, (-)-tartaric acid or (+)-10-5 camphorsulfonic acid.

The invention furthermore provides a medicament which comprises at least one of the cyclic substituted aminomethyl compounds of the general formulae IA and/or IB according to the invention and their pharmaceutically acceptable salts. The compounds according to the invention can be present here in the medicament according to the invention as isomerically pure, in particular enantiomERICALLY pure or diastereomERICALLY pure, compounds, but also as a racemic or non-racemic mixture. It is preferable here for the medicament to comprise a pharmaceutically acceptable salt of the compounds according to the invention, in particular a hydrochloride.

The invention also provides the use of at least one cyclic substituted aminomethyl compound of the general formulae IA and/or IB according to the invention, including their diastereomers or enantiomers, also as racemates or an enantiomer mixture in the form of their free base or of a salt formed with a physiologically tolerated acid, in particular the hydrochloride salt, for the preparation of a medicament for treatment of pain. The compounds according to the invention have proved to have an analgesic action in vivo. At the same time, the compounds according to the invention do not bind or scarcely bind to µ-receptors and have no specific activity on δ-receptors. It is thus found in the µ-opiate receptor binding test according to
P.L. Wood (P.L. Wood et al., Neuropharmacology, vol. 20, 1215 et seq. (1981)) that the compounds of the general formulae IA and IB according to the invention do not bind (0-20% inhibition at a concentration of 1 μM) or bind only very weakly (K_i > 1 μM) to the μ-receptor. In the δ-opiate receptor binding test according to L.K. Vaughn (L.K. Vaughn et al. Eur. J. Pharmacol., vol. 177, 99 et seq. (1990)), the compounds according to the invention show no specific activity on the δ-receptor (0-30% inhibition at a concentration of 1 μM; K_i > 1 μM).

Surprisingly, it has been found that the cyclic substituted aminomethyl compounds of the general formulae IA and/or IB according to the invention are very suitable for further indications, in particular for treatment of urinary incontinence, itching, tinnitus aurium and/or diarrhoea. The Application therefore also provides the use of at least one cyclic substituted aminomethyl compound of the general formulae IA and/or IB according to the invention, including a pharmaceutically acceptable salt, for the preparation of a medicament for treatment of urinary incontinence, itching tinnitus aurium and/or diarrhoea.

The present invention furthermore also provides pharmaceutical compositions which comprise at least one compound of the general formulae IA and/or IB as defined above or one of its pharmaceutically acceptable salts and one or more pharmaceutical auxiliary substances.

The medicaments and pharmaceutical compositions according to the invention can be present and administered as liquid, semi-solid or solid medicament forms and in the form of
e.g. injection solutions, drops, juices, syrups, suspensions, sprays, granules, tablets, pellets, patches, capsules, plasters, suppositories, ointments, creams, lotions, gels, emulsions or aerosols, and comprise, in addition to at least one cyclic substituted aminomethyl compound of the general formulae IA and/or IB according to the invention, pharmaceutical auxiliary substances according to the galenical form, such as e.g. carrier materials, fillers, solvents, diluents, surface-active substances, dyestuffs, preservatives, disintegrating agents, anti-friction agents, lubricants, flavourings and/or binders. These auxiliary substances can be, for example: water, ethanol, 2-propanol, glycerol, ethylene glycol, propylene glycol, polyethylene glycol, polypropylene glycol, glucose, fructose, lactose, sucrose, dextrose, molasses, starch, modified starch, gelatine, sorbitol, inositol, mannitol, microcrystalline cellulose, methylcellulose, carboxymethylcellulose, cellulose acetate, shellac, cetyl alcohol, polyvinylpyrrolidone, paraffins, waxes, naturally occurring and synthetic gums, acacia gum, alginates, dextran, saturated and unsaturated fatty acids, stearic acid, magnesium stearate, zinc stearate, glyceryl stearate, sodium lauryl sulfate, edible oils, sesame oil, coconut oil, ground nut oil, soya bean oil, lecithin, sodium lactate, polyoxyethylene and propylene fatty acid esters, sorbitan fatty acid esters, sorbic acid, benzoic acid, citric acid, ascorbic acid, tannic acid, sodium chloride, potassium chloride, magnesium chloride, calcium chloride, magnesium oxide, zinc oxide, silicon dioxide, titanium oxide, titanium dioxide, magnesium sulfate, zinc sulfate, calcium sulfate, potash, calcium phosphate, dicalcium phosphate, potassium bromide, potassium iodide, talc, kaolin, pectin, crosspovidone, agar and bentonite.
The choice of auxiliary materials and the amounts thereof to be employed depend on whether the medicament is to be administered orally, perorally, subcutaneously, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally, rectally or locally, for example to infections on the skin, the mucous membranes and the eyes. Formulations in the form of tablets, coated tablets, capsules, granules, drops, juices and syrups are suitable, inter alia, for oral administration, and solutions, suspensions, easily reconstitutable dry formulations and sprays are suitable for parenteral, topical and inhalatory administration. Cyclic substituted aminomethyl compounds of the general formulae IA and/or IB according to the invention in a depot in dissolved form or in a patch, optionally with the addition of agents which promote penetration through the skin, are suitable formulations for percutaneous administration. Formulation forms which can be used orally or percutaneously can release the cyclic substituted aminomethyl compounds of the general formulae IA and/or IB according to the invention in a delayed manner.

The medicaments and pharmaceutical compositions according to the invention are prepared with the aid of agents, devices, methods and processes which are well-known in the prior art of pharmaceutical formulation, such as are described, for example, in "Remington's Pharmaceutical Sciences", ed. A.R. Gennaro, 17th ed., Mack Publishing Company, Easton, Pa. (1985), in particular in part 8, sections 76 to 93.

Thus e.g. for a solid formulation, such as a tablet, the active compound of the medicament, i.e. a compound of the
general formulae IA and/or IB or one of its pharmaceutically acceptable salts, can be mixed with a pharmaceutical carrier, e.g. conventional tablet constituents, such as maize starch, lactose, sucrose, sorbitol, talc, magnesium stearate, dicalcium phosphate or gum, and pharmaceutical diluents, such as e.g. water, in order to form a solid preformulation composition which comprises a compound according to the invention or a pharmaceutically acceptable salt thereof in homogeneous distribution. Homogeneous distribution here is understood as meaning that the active compound is distributed uniformly over the entire preformulation composition, so that this can easily be divided into unit dose forms of the same action, such as tablets, pills or capsules. The solid preformulation composition is then divided into unit dose forms. The tablets or pills of the medicament according to the invention or of the compositions according to the invention can also be coated, or compounded in another manner in order to provide a dose form with delayed release. Suitable coating compositions are, inter alia, polymeric acids and mixtures of polymeric acids with materials such as e.g. shellac, cetyl alcohol and/or cellulose acetate.

The amount of active compound to be administered to the patient varies and depends on the weight, age and disease history of the patient, as well as on the mode of administration, the indication and the severity of the disease. 0.1 to 5,000 mg/kg, in particular 1 to 500 mg/kg, preferably 2 to 250 mg/kg of body weight of at least one cyclic substituted aminomethyl compound of the general formulae IA and/or IB according to the invention are usually administered.
The following examples serve to illustrate the present invention in more detail.

Silica gel 60 (0.040 - 0.063 mm) from E. Merck, Darmstadt was employed as the stationary phase for the column chromatography.

The thin layer chromatography analyses were carried out with HPTLC precoated plates, silica gel 60 F 254, from E. Merck, Darmstadt.

The mixture ratios of the mobile phases for all the chromatography analyses and separations are always stated in volume/volume.


\(^1\)H-NMR analyses to determine the stereochemistry (exo/endo double bond or E/Z configuration) of the inventions [sic] according to the invention were carried out with a 300 MHz DPX Advance NMR apparatus from Bruker.
Example 1

[1-(3-Methoxybenzyl)-3,4-dihydro-naphth-2-ylmethyl]-
dimethylamine hydrochloride

1st stage:
(1RS,2RS)-2-Dimethylaminomethyl-1-(3-methoxybenzyl)-
1,2,3,4-tetrahydro-naphth-1-ol

A solution of 8.13 g 2-dimethylaminomethyl-3,4-dihydro-
naphthalen-1-one in 20 ml dry diethyl ether was added
dropwise to a freshly prepared Grignard reagent of 1.46 g
magnesium filings and 8.8 ml 3-methoxybenzyl chloride in
50 ml dry diethyl ether at 20°C, while stirring. The
reaction mixture was heated under reflux for 3 hours,
decomposed by dropwise addition of 30 ml of a saturated
ammonium chloride solution and, after dilution with
distilled water, extracted three times with 50 ml diethyl
ether each time. The extracts were washed with a saturated
sodium chloride solution, dried over sodium sulfate and
evaporated in vacuo. The oily residue was purified by
column chromatography with ethyl acetate/methanol = 20/1 as
the eluting agent. 9.41 g (72.3% of th.) of the title
compound were obtained here as a diastereomeric mixture.

2nd stage:
[1-(3-Methoxybenzyl)-3,4-dihydro-naphth-2-ylmethyl]-
dimethylamine hydrochloride

6.51 g of the product from stage 1 were stirred with 75 ml
of a solution of hydrogen bromide in glacial acetic acid
(33% HBr) at 60°C for one hour. The mixture was then
evaporated in vacuo and the residue was taken up in 150 ml
water. The mixture was rendered alkaline with potassium carbonate and extracted three times with 50 ml methylene chloride each time. The extracts were washed with a saturated sodium chloride solution, dried over sodium sulfate and evaporated in vacuo. The crude base of the title compound obtained in this manner was converted into the hydrochloride with trimethylchlorosilane/water in 2-butanol.

Yield: 5.81 g (84.5% of th.)
Melting point: 202-204°C

Example 2

[1-(4-Chlorobenzyl-3,4-dihydro-naphth-2-ylmethyl)-dimethylamine hydrochloride]

The title compound was obtained using the procedure described in example 1, employing 4-chlorobenzyl chloride instead of the 3-methoxy compound in stage 1.

Melting point: 247 - 248°C

Example 3

3-(2-Dimethylaminomethyl-3,4-dihydro-naphth-1-ylmethyl)phenol hydrochloride

A: 4.71 g of the product from example 1, stage 1 were heated under reflux in 60 ml of a solution of hydrogen bromide in glacial acetic acid for 5 hours. The mixture was then evaporated in vacuo, the residue was taken up in 50 ml water and the mixture was
neutralized by addition of 1 N sodium hydroxide solution and finally rendered alkaline with ammonium hydroxide. It was extracted three times with 30 ml ethyl acetate each time and the extracts were dried over sodium sulfate and evaporated in vacuo. The crude base of the title compound which remained was converted into the hydrochloride with trimethylchlorosilane/water in 2-butanol.

Yield: 3.75 g (78.4% of th.)
Melting point: 151 - 153°C (decomp.)

The title compound could be obtained by the following route:

B: 40 ml of a solution of diisobutylaluminium hydride in toluene (20 wt.%) were added to a suspension of 2.06 g of the product from example 1 in 20 ml dry toluene and the mixture was heated under reflux for 12 hours. After cooling, decomposition was carried out by dropwise addition of ethanol, finally mixed with water, and the mixture was evaporated in vacuo. 30 ml methanol were added to the residue and the mixture was filtered over filtering earth. The filtrate was evaporated and the crude base of the title compound obtained in this manner was converted with trimethylchlorosilane/water in 2-butanol into the hydrochloride, the melting properties of which were identical to those of the product obtained above.

Yield: 1.58 g (79.6% of th.)
Example 4

Using the procedure described in example 3, method A and employing corresponding tertiary alcohols, the following were obtained analogously:

4a: 5-(4-Chlorobenzyl)-6-dimethylaminomethyl-7,8-dihydro-naphth-2-ol hydrochloride
Melting point: 110°C (decomp.)

4b: [1-(2,4-Dichlorobenzyl)-3,4-dihydro-naphth-2-ylmethyl]-dimethylamine hydrochloride
Melting point: 208 - 209°C

4c: 5-(4-Chlorobenzyl)-6-dimethylaminomethyl-7,8-dihydro-naphth-1-ol hydrochloride
Melting point: 136 - 139°C

4d: [5-(4-Chlorobenzyl)-8,9-dihydro-7H-benzocyclohepten-6-ylmethyl]-dimethylamine hydrochloride
Melting point: 240 - 243°C

4e: E-(5RS)-[5-(4-Chlorobenzylidene)-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-ylmethyl]-dimethylamine hydrochloride
Melting point: 181 - 183°C

As products of the same batch, the example compounds 4d and 4e were separated in the form of the free bases by column chromatography with ethyl acetate/methanol = 9/1 as the eluting agent.
4f: 6-Dimethylaminomethyl-5-(3-hydroxybenzyl)-7,8-dihydronaphth-2-ol hydrochloride
Melting point: 89°C (decomp.)

Example 5

[1-(2-Methoxybenzyl)-3,4-dihydro-naphth-2-ylmethyl]-dimethylamine hydrochloride (5a)
and
E-(2RS)-[1-(2-Methoxybenzylidene)-1,2,3,4-tetrahydro-naphth-2-ylmethyl]-dimethylamine hydrochloride (5b)

A solution of 7.06 g (1RS,2RS)-2-dimethylaminomethyl-1-(2-methoxy-benzyl)-1,2,3,4-tetrahydronaphth-1-ol (prepared analogously to example 1, stage 1 from 2-methoxybenzyl chloride and 2-dimethylaminomethyl-3,4-dihydronaphthalen-1-one) in 45 ml formic acid was stirred at 20°C for 3 hours. It was diluted with 100 ml water and rendered alkaline by addition of potassium carbonate in portions up to pH 9.

The mixture was extracted three times with 50 ml methylene chloride each time. The extracts were washed with saturated sodium chloride solution, dried over sodium sulfate and evaporated in vacuo. The residue was separated by column chromatography with ethyl acetate as the eluting agent, the two title compounds being obtained as bases, which were converted into the hydrochlorides with trimethylchlorosilane/water in 2-butanone.

5a:  Yield: 3.12 g (51.5% of th.)
      Melting point: 181 - 183°C

5b:  Yield: 2.38 g (39.3% of th.)
      Melting point: 228 - 230°C
Example 6

3-(4-Dimethylaminomethyl-2,3-dihydro-benzo[b]oxepin-5-ylmethyl)-phenol hydrochloride (6a),

E-(4RS)3-(4-Dimethylaminomethyl-3,4-dihydro-2H-benzo[b]oxepin-5-ylidene-methyl)-phenol hydrochloride (6b) and

Z-(4RS)3-(4-Dimethylaminomethyl-3,4-dihydro-2H-benzo[b]oxepin-5-ylidene-methyl)-phenol hydrochloride (6c)

A mixture of 4.78 g (4RS,5RS)-4-dimethylaminomethyl-5-(3-methoxybenzyl)-2,3,4,5-tetrahydrobenzo[b]oxepin-5-ol (prepared from 3-methoxybenzylmagnesium chloride and 4-dimethylaminomethyl-3,4-dihydro-2H-benzo[b]oxepin-5-one analogously to example 1, stage 1), 28 ml methanesulfonic acid and 3.20 g methionine was stirred at 40°C for 4 days. Ice was then added and the mixture was cautiously rendered alkaline with sodium bicarbonate. It was extracted three times with 30 ml ethyl acetate each time and the extracts were washed with a saturated sodium chloride solution, dried over sodium sulfate and evaporated in vacuo. The crude product mixture obtained in this manner was separated by column chromatography with ethyl acetate and the individual compounds were converted into their hydrochlorides with trimethylchlorosilane/water in 2-butanone.

6a: Yield: 0.88 g (18.1% of th.)
Melting point: 194 - 196°C

6b: Yield: 0.76 g (15.7% of th.)
Melting point: 120°C (decomp.)
6c: Yield: 1.29 g (26.5% of th.)
Melting point: 154°C (decomp.)

Example 7

\[5-(4\text{-Chlorobenzyl})-2,3\text{-dihydro-benzo}[b]\text{-oxepin-4-ylmethyl}]\text{-dimethylamine hydrochloride (7a),}
\]
\[E-(4RS)[5-(4\text{-Chlorobenzylidene})-2,3,4,5\text{-tetrahydro-benzo}[b]\text{-oxepin-4-yl-methyl}]\text{-dimethylamine hydrochloride (7b)}
\]
and
\[Z-(4RS)[5-(4\text{-Chlorobenzylidene})-2,3,4,5\text{-tetrahydro-benzo}[b]\text{-oxepin-4-yl-methyl}]\text{-dimethylamine hydrochloride (7c)}
\]

7.27 g (4RS,5RS)-5-(4-chlorobenzyl)-4-dimethylaminomethyl-2,3,4,5-tetrahydrobenzo[b]oxepin-5-ol were reacted with 43 ml methanesulfonic acid and 4.81 g methionine analogously to the procedure described in example 6. After similarly analogous working up, separation of the product and salt formation, the title compounds were obtained in the form of white crystals.

7a: Yield: 3.07 g (40.1% of th.)
Melting point: 215 - 217°C

7b: Yield: 0.93 g (12.1% of th.)
Melting point: 92°C (decomp.)

7c: Yield: 1.69 g (22.1% of th.)
Melting point: 162 - 164°C
Example 8

2-Chloro-5-[(4-dimethylaminomethyl)-2,3-dihydrobenzo[b]oxepin-5-ylmethyl]-phenol hydrochloride

0.80 g (42.7% of th.) of the title compound were obtained from 1.85 g (4RS,5RS)-5-(4-chloro-3-methoxybenzyl)-4-dimethylaminomethyl-2,3,4,5-tetrahydro-benzo[b]oxepin-5-ol, 10 ml methanesulfonic acid and 1.12 g methionine using the procedure described in example 6.

Melting point: 220 - 222°C

Example 9

3-[(4-Dimethylaminomethyl)-2,3-dihydro-benzo[b]thiepin-5-ylmethyl]-phenol hydrochloride (9a) and

Z-(4RS)-3-(4-Dimethylaminomethyl)-3,4-dihydro-2H-benzo[b]thiepin-5-ylidenemethyl]-phenol hydrochloride (9b)

The title compounds were obtained from 8.00 g (4RS,5RS)-4-dimethylaminomethyl-5-(3-methoxybenzyl)-2,3,4,5-tetrahydro-benzo[b]thiepin-5-ol, 45 ml methanesulfonic acid and 5.11 g methionine using the procedure described in example 6, after separation of the products by column chromatography with ethyl acetate/methanol = 3/1 as the eluting agent and conversion into the hydrochlorides.

9a: Yield: 3.43 g (42.2% of th.)

Melting point: 92% (decomp.)
9b: Yield: 1.57 g (19.4% of th.)
Melting point: 209 - 210°C

Example 10

(1RS)-3-(4-Dimethylaminomethyl-1-oxo-2,3-dihydro-
benzo[b]thiepin-5-yl-methyl)-phenol hydrochloride

0.60 g of the product from example 9a in 6 ml acetic acid
and 0.5 ml of an aqueous solution of hydrogen peroxide
(30 wt.% H₂O₂) were stirred at 20°C for 2 hours. The
mixture was diluted with 30 ml water and rendered alkaline
first with 3N sodium hydroxide solution and then with
potassium carbonate to a pH of 8. The mixture was
extracted three times with 20 ml ethyl acetate each time.
The combined extracts were washed with saturated sodium
chloride solution, dried over sodium sulfate and evaporated
in vacuo. The residue was converted into the hydrochloride
with trimethylchlorosilane/water in 2-butanone. 0.53 g
(84.5% of th.) of the title compound was obtained in this
manner.

Melting point: 96°C (decomp.)

Example 11

[5-(4-Chlorobenzyl)-2,3-dihydro-benzo[b]thiepin-4-
yl)methyl]-dimethylamine hydrochloride

3.00 g (4RS,5RS)-5-(4-chlorobenzyl)-4-dimethylaminomethyl-
2,3,4,5-tetrahydro-benzo[b]thiepin-5-ol (prepared as
described in example 1, stage 1 from (4RS)-4-
dimethylaminomethyl-3,4-dihydro-2H-benzo[b]thiepin-5-one
and 4-chlorobenzylmagnesium chloride), 17 ml methanesulfonic acid and 1.90 g methionine were stirred at 50°C for 7 days. After working up, purification and conversion into the hydrochloride, as described in example 6, 1.87 g (59.4% of th.) of the title compound were obtained.

Melting point: 223 - 224°C

Example 12

\((1R,S)-[5-(4-Chlorobenzyl)-1-oxo-2,3-dihydro\benzo[b]thiepin-4-ylmethyl]-dimethylamine hydrochloride\)

0.25 g of the product from example 11 was oxidized in 2.3 ml acetic acid with 0.2 ml of an aqueous solution of hydrogen peroxide (30 wt.% \(\text{H}_2\text{O}_2\)) using the procedure described in example 10. After similarly analogous working up and hydrochloride formation, 0.21 g (80.6% of th.) of the title compound was obtained.

Melting point: 227 - 229°C

Example 13

\(E-(4RS)-[5-(3-Methoxybenzylidene)-2,3,4,5-tetrahydro\benzo[b]oxepin-4-ylmethyl]-dimethylamine hydrochloride\)

1.00 g \((4RS,5RS)-4\)-dimethylaminomethyl-5-(3-methoxybenzyl)-2,3,4,5-tetrahydro-benzo[b]oxepin-5-ol (see example 6) and 48 ml 6N hydrochloric acid were stirred at 20°C for 24 h and at 50°C for 8 h. The mixture was then rendered alkaline with 6N sodium hydroxide solution and extracted
three times with 20 ml ethyl acetate each time. The extracts were washed with a saturated sodium chloride solution, dried over sodium sulfate and evaporated in vacuo. The residue was purified by column chromatography with ethyl acetate as the eluting agent. After conversion into the hydrochloride with a solution of hydrogen chloride in diethyl ether, 0.72 g (68.6% of th.) of the title compound was obtained.

10 Melting point: 170 - 172°C

Example 14

E-(4RS)-(5-(3-Methoxybenzylidene)-2,3,4,5-tetrahydrobenzo[b]thiepin-4-ylmethyl]-dimethylamine hydrochloride (14a) and its Z isomer (14b)

5.00 g (4RS,5RS)-4-dimethylaminomethyl-5-(3-methoxybenzyl)-2,3,4,5-tetrahydro-benzo[b]thiepin-5-ol (see example 9) were reacted with 230 ml 6N hydrochloric acid by the procedure described in example 13. After similarly analogous working up, separation of the double bond isomers by column chromatography with ethyl acetate/methanol = 3/1 and conversion into the hydrochloride, the title compounds were obtained in the form of white crystals.

14a: Yield: 1.10 g (20.9% of th.)
Melting point: 166 - 169°C

30 14b: Yield: 2.56 g (48.7% of th.)
Melting point: 164 - 167°C
Pharmaceutical formulation of a medicament according to the invention

1 g of the hydrochloride of compound 6b (E-(4RS)3-(4-
5 dimethylaminomethyl-3,4-dihydro-2H-benzo[b]oxepin-5-
ylidenemethyl)-phenol hydrochloride) was dissolved in 1 l
water for injection purposes at room temperature and the
solution was then adjusted to isotonic conditions by
addition of NaCl (sodium chloride).

Pharmacological investigation of the compounds according to the invention

The antinociceptive activity of the compounds according to the invention was investigated in mice in the
phenylquinone-induced writhing test, modified by I.C.
Hendershot, J. Forsaith, J. Pharmacol. Exp. Ther. 125, 237-
240 (1959). Male NMRI mice weighing 25-30 g were employed
for this. Groups of 10 animals per substance dose received
0.3 ml/mouse of a 0.02% aqueous solution of phenylquinone
(phenylbenzoquinone, Sigma, Deisenhofen; preparation of the
solution with the addition of 5% ethanol and storage in a
water bath at 45°C) administered intraperitoneally
10 minutes after intravenous administration of a compound
according to the invention. The animals were placed
individually in observation cages. The number of pain-
induced stretching movements (so-called writhing reactions
= straightening of the body with stretching of the hind
extremities) was counted by means of a push-button counter
for 5 - 20 minutes after the administration of
phenylquinone.
The ED$_{50}$ values of the writhing reaction were calculated by means of regression analysis (evaluation program, Martens EDV Service, Eckental) from the dose-dependent decrease in writhing reactions compared with animal groups investigated in parallel to which no compound according to the invention was administered.

The majority of the substances were tested in the standard dose of 10 mg/kg. The percentage inhibition (% inhibition) of the writhing reactions by a substance was then calculated according to the following equation:

\[
\text{% inhibition} = 100 - \left( \frac{\text{writhing reaction treat. animals}}{\text{writhing reaction control}} \right) \times 100
\]

("treat." = treated).

The results are summarized in table 1 for selected compounds.

<table>
<thead>
<tr>
<th>Example no.</th>
<th>Writhing test, mouse, i.v. decrease in writhing reactions or ED$_{50}$ [mg/kg]</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>6.85 (61.5%)</td>
</tr>
<tr>
<td>3</td>
<td>93%</td>
</tr>
<tr>
<td>4e</td>
<td>69%</td>
</tr>
<tr>
<td>4c</td>
<td>84%</td>
</tr>
<tr>
<td>7c</td>
<td>79%</td>
</tr>
<tr>
<td>6a</td>
<td>95%</td>
</tr>
<tr>
<td>6b</td>
<td>91% [21.5 mg/kg]</td>
</tr>
<tr>
<td>6c</td>
<td>78%</td>
</tr>
</tbody>
</table>
The results reproduced in table 1 show that the compounds according to the invention, in particular example compound no. 6b \((E)-(4RS)3-(4\text{-dimethylaminomethyl}-3,4\text{-dihydro}-2H\text{-benzo[\text{b}]oxepin-5-ylidenemethyl})\text{-phenol hydrochloride})\), which already causes 91% inhibition at a dose of 2.15 mg/kg body weight, have an analgesic action in vivo. At the same time the compounds according to the invention do not bind or scarcely bind to \(\mu\)-receptors and have no specific activity on \(\delta\)-receptors.
Claims

1. Cyclic substituted aminomethyl compounds of the general formula IA and/or IB

\[
\begin{align*}
&\text{IA} \quad \text{IB} \\
&\left(\text{CH}_2\right)_n R^5 \\
&\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4, \text{R}^6 \\
\end{align*}
\]

wherein

- \( \text{R}^1 \) denotes \( H, F, \text{Cl}, \text{OH}, \text{O-CH}_3, \text{O-(C}_2\text{-6-alkyl)}, \text{O-(C}_3\text{-7-cycloalkyl)}, \text{CH}_3, \text{C}_2\text{-6-alkyl, CH}_2\text{F, CHF}_2 \text{ or CF}_3 \), in each case in the 2-, 3-, 4-, 5- or 6-position of the phenyl ring,

- \( \text{R}^2 \) denotes \( H, F, \text{Cl}, \text{CH}_3, \text{C}_2\text{-6-alkyl}, \text{CH}_2\text{F, CHF}_2 \text{ or CF}_3 \), in each case in the 2-, 3-, 4-, 5- or 6-position of the phenyl ring,

- \( \text{R}^3 \) and \( \text{R}^4 \) independently of one another denote \( H, F, \text{Cl}, \text{OH}, \text{O-CH}_3, \text{O-(C}_2\text{-6-alkyl)}, \text{O-(C}_3\text{-7-cycloalkyl)}, \text{CH}_3, \text{C}_2\text{-6-alkyl}, \text{CH}_2\text{F, CHF}_2, \text{CF}_3, \text{O-aryl, aryl or heterocyclyl, in each case in the } \alpha-, \beta-, \gamma- \text{ and/or } \delta- \text{-position of the aromatic ring,} \)
R⁵ and R⁶ independently of one another denote CH₃, C₂-₆-alkyl, C₃-₇-cycloalkyl, CH₂-(C₃-₇-cycloalkyl), aryl, (C₁-₆-alkyl)-aryl, heterocyclyl or (C₁-₆-alkyl)-heterocyclyl,

5

X denotes CH₂, O, S, SO or SO₂,

n is 0, 1, 2 or 3 if X denotes CH₂ and is 1, 2 or 3 if X denotes O, S, SO or SO₂,

10

and the configuration of the exocyclic double bond in compounds of the general formula IB is E or Z,

and their pharmaceutically acceptable salts.

15

2. Cyclic substituted aminomethyl compounds of the general formula IA according to claim 1, wherein, independently of one another, R¹ denotes OH, O-CH₃ or Cl, R² denotes H or Cl, R³ denotes H or OH, R⁴ denotes H, R⁵ and R⁶ denote CH₃ and X denotes CH₂, O, S or SO and n is 1 or 2, and their pharmaceutically acceptable salts.

20

3. Cyclic substituted aminomethyl compounds of the general formula IA according to one of claims 1 or 2, wherein, independently of one another, R¹ denotes 3-OH, 2-O-CH₃, 3-O-CH₃ or 4-Cl, R² denotes H, 2-Cl or 4-Cl, R³ denotes H, α-OH or β-OH, R⁴ denotes H, R⁵ and R⁶ denote CH₃ and X denotes CH₂, O, S or SO and n is 1 or 2, and their pharmaceutically acceptable salts.
4. Cyclic substituted aminomethyl compounds of the general formula IB according to claim 1, wherein \( \text{R}^1 \) denotes \( \text{OH} \), \( \text{O-CH}_3 \) or \( \text{Cl} \), \( \text{R}^2 \), \( \text{R}^3 \) and \( \text{R}^4 \) denote \( \text{H} \), \( \text{R}^5 \) and \( \text{R}^6 \) denote \( \text{CH}_3 \) and \( \text{X} \) denotes \( \text{CH}_2 \), \( \text{O} \) or \( \text{S} \), \( \text{n} \) is 1 or 2 and the configuration of the exocyclic double bond is \( \text{E} \) or \( \text{Z} \), and their pharmaceutically acceptable salts.

5. Cyclic substituted aminomethyl compounds of the general formula IB according to one of claims 1 or 4, wherein \( \text{R}^1 \) denotes 3-\( \text{OH} \), 2-\( \text{O-CH}_3 \), 3-\( \text{O-CH}_3 \) or 4-\( \text{Cl} \), \( \text{R}^2 \), \( \text{R}^3 \) and \( \text{R}^4 \) denote \( \text{H} \), \( \text{R}^5 \) and \( \text{R}^6 \) denote \( \text{CH}_3 \) and \( \text{X} \) denotes \( \text{CH}_2 \), \( \text{O} \) or \( \text{S} \), \( \text{n} \) is 1 or 2 and the configuration of the exocyclic double bond is \( \text{E} \) or \( \text{Z} \), and their pharmaceutically acceptable salts.

6. Cyclic substituted aminomethyl compounds according to one of claims 1 to 5, wherein the compounds are in the form of a mixture of the isomers with an endocyclic double bond according to the general formula IA and with an exocyclic double bond according to the general formula IB.

7. Cyclic substituted aminomethyl compounds of the general formulae IA and/or IB according to one of claims 1 to 6 in the form of their racemates, in the form of the pure enantiomers or in the form of mixtures of the enantiomers in any desired mixture ratio, and their pharmaceutically acceptable salts.

8. Cyclic substituted aminomethyl compounds according to one of claims 1 to 7, wherein the amino compounds are chosen from
[1-(4-chlorobenzyl)-3,4-dihydro-naphth-2-ylmethyl]-dimethylamine,
3-(2-dimethylaminomethyl-3,4-dihydro-naphth-1-ylmethyl)-phenol,
5-(4-chlorobenzyl)-6-dimethylaminomethyl-7,8-dihydro-naphth-1-ol,
E-(5RS)-[5-(4-chlorobenzylidene)-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-ylmethyl]-dimethylamine,
Z-(4RS)-[5-(4-chlorobenzylidene)-2,3,4,5-tetrahydrobenzo[b]oxepin-4-ylmethyl]-dimethylamine,
3-(4-dimethylaminomethyl-2,3-dihydro-benzo[b]oxepin-5-ylmethyl)-phenol,
E-(4RS)-3-(4-dimethylaminomethyl-3,4-dihydro-2H-benzo[b]oxepin-5-ylidenemethyl)-phenol or
Z-(4RS)-3-(4-dimethylaminomethyl-3,4-dihydro-2H-benzo[b]oxepin-5-ylidenemethyl)-phenol
and their pharmaceutically acceptable salts, in particular their hydrochlorides.

9. Process for the preparation of compounds of the general formulae IA and/or IB
wherein

R¹ denotes H, F, Cl, OH, O-CH₃, O-(C₂₋₆-alkyl),
O-(C₃₋₇-cycloalkyl), CH₃, C₂₋₆-alkyl, CH₂F,
CHF₂ or CF₃, in each case in the 2-, 3-, 4-, 5- or 6-position of the phenyl ring,

R² denotes H, F, Cl, CH₃, C₂₋₆-alkyl, CH₂F, CHF₂
or CF₃, in each case in the 2-, 3-, 4-, 5- or 6-position of the phenyl ring,

R³ and R⁴ independently of one another denote H, F,
Cl, OH, O-CH₃, O-(C₂₋₆-alkyl), O-(C₃₋₇-cycloalkyl), CH₃, C₂₋₆-alkyl, CH₂F, CHF₂, CF₃,
O-aryl, aryl or heterocyclyl, in each case in the α-, β-, γ- and/or δ-position of the aromatic ring,

R⁵ and R⁶ independently of one another denote CH₃, C₂₋₆-alkyl,
C₃₋₇-cycloalkyl, CH₂-(C₃₋₇-cycloalkyl),
aryl, (C₁₋₆-alkyl)-aryl, heterocyclyl or
(C₁₋₆-alkyl)-heterocyclyl,

X denotes CH₂, O, S, SO or SO₂,

n is 0, 1, 2 or 3 if X denotes CH₂ and is 1, 2 or 3 if X denotes O, S, SO or SO₂

and the configuration of the exocyclic double bond in
compounds of the general formula IB is E or Z,
characterized by a process step (a) which comprises reaction of a tertiary alcohol of the general formula II

\[
\begin{align*}
\text{II} & \quad \text{wherein } R^1 \text{ to } R^6, \text{ } X \text{ and } n \text{ are as defined above, with an acid.}
\end{align*}
\]

10. Process according to claim 9, characterized in that process step (a) comprises conversion of a tertiary alcohol of the general formula II in which at least one of the radicals \( R^1, R^3 \) and \( R^4 \) denotes \( \text{O-CH}_3 \) into compounds of the general formulae IA and/or IB in which the radicals \( R^1, R^3 \) and \( R^4 \) denote \( \text{OH} \), when the corresponding radicals \( R^1, R^3 \) and \( R^4 \) in the tertiary alcohol of the general formula II denote \( \text{O-CH}_3 \), with a reagent from the group which comprises hydrogen bromide in glacial acetic acid, concentrated hydrobromic acid and methanesulfonic acid/methionine.

11. Process according to claim 9, characterized in that, before process step (a), a process step (b) is carried out which comprises conversion of a tertiary alcohol of the general formula III
wherein

$R^2, R^5, R^6, X$ and $n$ are as defined in claim 9,

$R^7$ denotes H, F, Cl, O-CH$_3$, O-(C$_2$-$\alpha$-alkyl), O-(C$_3$-$\gamma$-cycloalkyl), O-CH$_2$-phenyl, O-SiR$_{10}$R$_{11}$R$_{12}$, wherein $R^{10}$, $R^{11}$ and $R^{12}$ independently of one another are CH$_3$, C$_2$-$\beta$-alkyl or phenyl, CH$_3$, C$_2$-$\alpha$-alkyl, CH$_2$F, CHF$_2$ or CF$_3$, in each case in the 2-, 3-, 4-, 5- or 6-position of the phenyl ring,

$R^8$ and $R^9$ independently of one another denote H, F, Cl, O-CH$_3$, O-(C$_2$-$\alpha$-alkyl), O-(C$_3$-$\gamma$-cycloalkyl), O-CH$_2$-phenyl, O-SiR$_{10}$R$_{11}$R$_{12}$, wherein $R^{10}$, $R^{11}$ and $R^{12}$ independently of one another are CH$_3$, C$_2$-$\beta$-alkyl or phenyl, CH$_3$, C$_2$-$\alpha$-alkyl, CH$_2$F, CHF$_2$, CF$_3$, O-aryl, aryl or heterocyclyl, in each case in the $\alpha$-, $\beta$-, $\gamma$- and/or $\delta$-position of the aromatic ring,

and at least one of the radicals $R^7$, $R^8$ and $R^9$ is O-CH$_3$, O-(C$_2$-$\alpha$-alkyl), O-(C$_3$-$\gamma$-cycloalkyl), O-CH$_2$-phenyl or O-SiR$_{10}$R$_{11}$R$_{12}$,
into a tertiary alcohol of the general formula II according to claim 9 in which \( R^1, R^3 \) and \( R^4 \) is [sic] in each case OH, when the corresponding radical \( R^7, R^8 \) or \( R^9 \) in the formula III is \( O-CH_3, O-(C_2-6-alkyl), O-(C_3-7-cycloalkyl), O-CH_2-phenyl \) or \( O-SiR^{10}R^{11}R^{12} \).

12. Process according to one of claims 9 to 11, characterized in that, for the preparation of the tertiary alcohols of the general formulae II or III, before process steps (a) and (b) a process step (c) is carried out, which comprises reaction of a ketone of the general formula IV

\[
\begin{align*}
\text{IV} & \\
\end{align*}
\]

wherein \( R^5, R^6, X \) and \( n \) are as defined in claim 9 and \( R^8 \) and \( R^9 \) are as defined in claim 11,

with an organometallic compound of the general formula V

\[
\begin{align*}
\text{V} & \\
\end{align*}
\]
wherein $R^2$ is as defined in claim 9 and $R^3$ is as defined in claim 11 and $Z$ denotes MgCl, MgBr, MgI or Li.

13. Process according to one of claims 9 to 12, characterized in that compounds of the general formulae IA and/or IB where $X = S$ are converted in a process step (d) into compounds of the general formulae IA and/or IB where $X = SO$ and/or $SO_2$ using an oxidizing agent.

14. Process according to one of claims 9 to 13, characterized in that after process step (a) and optionally before or after process step (d), a process step (e) is carried out, which comprises conversion of compounds of the general formula IA and/or IB in which at least one of the radicals $R^1$, $R^3$ and $R^4$ denotes O-CH$_3$ into compounds of the general formulae IA and/or IB in which the corresponding radical(s) $R^1$, $R^3$ and $R^4$ denote(s) OH.

15. Process according to one of claims 9 to 14, characterized in that after process step (a) or (d) or (e) a process step (f) is carried out, which comprises conversion of the compounds of the general formulae IA and/or IB into their pharmaceutically acceptable salts.

16. Process according to one of claims 9 to 15, characterized in that after process step (a) or before or after process step (d) or before or after process step (e) or after process step (f) a process step (g)
is carried out, which comprises separation of the compounds of the general formulae IA and IB and optionally of their pharmaceutically acceptable salts.

17. Tertiary alcohol of the general formula II or III

\[
\text{II} \quad \text{III}
\]

wherein R\(^1\) to R\(^6\), X and n are as defined in claim 9 and R\(^7\) to R\(^9\) are as defined in claim 11.

18. Medicament comprising at least one compound of the general formulae IA and/or IB or one of its pharmaceutically acceptable salts according to one of claims 1 to 8.

19. Use of a compound of the general formulae IA and/or IB or of one of its pharmaceutically acceptable salts according to one of claims 1 to 8 for the preparation of a medicament for treatment of pain.

20. Use of a compound of the general formulae IA and/or IB or of one of its pharmaceutically acceptable salts according to one of claims 1 to 8 for the preparation of a medicament for treatment of urinary incontinence, itching, tinnitus aurium and/or diarrhoea.
21. Pharmaceutical composition which comprises at least one compound of the general formulae IA and/or IB or one of its pharmaceutically acceptable salts according to one of claims 1 to 8 and one or more pharmaceutical auxiliary substances.

22. Method for the treatment of states of pain in a mammal and/or human, characterized in that a therapeutically active amount of a compound of the general formula IA and/or IB or one of its pharmaceutically acceptable salts according to one of claims 1 to 8 is administered.

23. Method for the treatment of urinary incontinence, itching, tinnitus aurium and/or diarrhoea in a mammal and/or human, characterized in that a therapeutically active amount of a compound of the general formula IA and/or IB or one of its pharmaceutically acceptable salts according to one of claims 1 to 8 is administered.